Chitosan-based delivery systems for protein therapeutics and antigens.

By M. Amidi, E. Mastrobattista, W. Jiskoot, W. E. Hennink. Advanced Drug Delivery Reviews, 2010

604 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent advances of chitosan nanoparticles as drug carriers (2011, methodology): “11 In the chitosan–Arabic gelatin nanoparticles of insulin prepared by Avadi et al 12 minimum particle size and maximum combining rate with insulin were reached at a chitosan concentration of 10 mg/mL, Arabic gelatin concentration of 5 mg/mL, and insulin concentration of 5 mg/mL. 12 As ionic…”
Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. (2012, background): “Due to the advantageous biological properties f chitosan, such as relative non-toxicity, biocompatibility, iodegradability, cationic properties, bioadhesive characteristics nd permeability-enhancing properties, chitosan-based particles ave been extensively studied for delivery of anti-cancer agents,”
Chitosan—A versatile semi-synthetic polymer in biomedical applications (2011, neutral): “been studied [325–344].”